Capricor Therapeutics (NASDAQ:CAPR) Given Buy Rating at HC Wainwright

Capricor Therapeutics (NASDAQ:CAPR)‘s stock had its “buy” rating reiterated by equities researchers at HC Wainwright in a note issued to investors on Tuesday,Benzinga reports. They presently have a $60.00 price objective on the biotechnology company’s stock. HC Wainwright’s price objective points to a potential upside of 70.07% from the stock’s previous close.

Several other analysts also recently weighed in on the stock. Weiss Ratings restated a “sell (e+)” rating on shares of Capricor Therapeutics in a research report on Monday, December 29th. Roth Mkm boosted their price target on shares of Capricor Therapeutics from $12.00 to $13.00 and gave the company a “buy” rating in a research report on Tuesday, November 11th. iA Financial set a $48.00 target price on Capricor Therapeutics in a research report on Wednesday, December 3rd. Oppenheimer upped their target price on Capricor Therapeutics from $22.00 to $54.00 and gave the company an “outperform” rating in a research report on Monday, December 8th. Finally, Maxim Group boosted their price objective on Capricor Therapeutics from $25.00 to $50.00 and gave the company a “buy” rating in a research note on Thursday, December 4th. Nine equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $40.82.

Capricor Therapeutics Stock Performance

NASDAQ CAPR traded up $4.65 during trading on Tuesday, reaching $35.28. 2,454,245 shares of the company’s stock were exchanged, compared to its average volume of 1,258,353. The company has a 50 day moving average price of $25.38 and a two-hundred day moving average price of $15.93. The stock has a market cap of $1.61 billion, a P/E ratio of -19.60 and a beta of 0.37. Capricor Therapeutics has a 1 year low of $4.30 and a 1 year high of $40.37.

Hedge Funds Weigh In On Capricor Therapeutics

A number of large investors have recently bought and sold shares of the company. Goldman Sachs Group Inc. increased its stake in shares of Capricor Therapeutics by 39.5% during the first quarter. Goldman Sachs Group Inc. now owns 411,141 shares of the biotechnology company’s stock worth $3,902,000 after acquiring an additional 116,373 shares during the period. Ellerson Group Inc. ADV purchased a new position in Capricor Therapeutics in the second quarter worth $170,000. Simplify Asset Management Inc. acquired a new stake in Capricor Therapeutics in the second quarter valued at $397,000. Geode Capital Management LLC boosted its position in shares of Capricor Therapeutics by 6.8% during the 2nd quarter. Geode Capital Management LLC now owns 963,080 shares of the biotechnology company’s stock worth $9,565,000 after purchasing an additional 61,701 shares in the last quarter. Finally, Citizens Financial Group Inc. RI grew its stake in shares of Capricor Therapeutics by 249.2% during the 2nd quarter. Citizens Financial Group Inc. RI now owns 35,000 shares of the biotechnology company’s stock worth $348,000 after purchasing an additional 24,977 shares during the period. Hedge funds and other institutional investors own 21.68% of the company’s stock.

About Capricor Therapeutics

Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for cardiovascular and rare diseases. Headquartered in Beverly Hills, California, the company leverages proprietary cardiosphere-derived cell (CDC) technology to address conditions characterized by inflammation, fibrosis, and tissue degeneration. Since its founding, Capricor has advanced its lead candidate through multiple clinical trials and has built a pipeline that spans both cell therapy and extracellular vesicle (exosome) platforms.

The company’s leading product candidate, CAP-1002, comprises allogeneic CDCs and is being evaluated in indications such as Duchenne muscular dystrophy (DMD) and COVID-19-related heart injury.